Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + FOLFOX
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab + FOLFOX is a combination therapy that pairs the PD-1 inhibitor toripalimab with the FOLFOX chemotherapy regimen (folinic acid, fluorouracil, and oxaliplatin). This combination demonstrates synergistic effects in treating various cancers. FOLFOX works by destroying rapidly dividing cells through different mechanisms, while toripalimab enhances immune response against cancer cells by blocking the PD-1 pathway. Clinical trials have shown promising results for this combination in treating advanced hepatocellular carcinoma (HCC) with high-risk features and locally advanced colorectal cancer, with improved progression-free survival rates and pathological complete response rates compared to chemotherapy alone.
- Brand names
- Tuoyi + FOLFOX
- Other names
- JS001 combined with FOLFOXJS-001 combined with FOLFOXJS 001 combined with FOLFOXToripalimab plus FOLFOXtoripalimab + oxaliplatin + leucovorin + 5-fluorouracil
02
Targets
TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + FOLFOX.